Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized double-blind placebo-controlled single and multiple ascending dose study of ZGN-1061
NL-OMON42985Phase 1Active, not recruiting
- Sponsor
- Zafgen, Inc.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aclimostat in obesity and metabolic syndrome (MS) (9 cohorts), sponsored by Zafgen, Inc. Primary endpoint: Safety and tolerability. Started Jun 2016; status: active, not recruiting.
02
Drugs
aclimostat
03
Conditions
obesitymetabolic syndrome (MS)
Beyond the preview
Go deeper on NL-OMON42985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42985.